Published in Eur J Pediatr on February 11, 2009
Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study. Hum Vaccin Immunother (2014) 0.88
Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008. BMC Res Notes (2011) 0.83
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med (2013) 0.82
Disease burden of rotavirus gastroenteritis in children up to 5 years of age in two Swiss cantons: paediatrician- and hospital-based surveillance. Eur J Pediatr (2009) 0.81
Nosocomial rotavirus infection: An up to date evaluation of European studies. Hum Vaccin Immunother (2016) 0.81
Burden of rotavirus infections in Liguria, Northern Italy: hospitalisations and potential savings by vaccination. Eur J Clin Microbiol Infect Dis (2011) 0.80
Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Vaccine (2013) 0.79
Socio-demographic, Clinical and Laboratory Features of Rotavirus Gastroenteritis in Children Treated in Pediatric Clinic. Mater Sociomed (2013) 0.75
Group A rotaviruses in children with gastroenteritis in a Canadian pediatric hospital: The prevaccine era. Can J Infect Dis Med Microbiol (2013) 0.75
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis (2003) 9.44
Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis (1990) 4.42
Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA (1998) 2.86
Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. MMWR Morb Mortal Wkly Rep (1999) 2.42
Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis (1996) 1.98
Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics (1996) 1.77
The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis (1996) 1.73
Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet (1997) 1.70
Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis (2000) 1.51
Impact of rotavirus infection at a large pediatric hospital. J Infect Dis (1990) 1.43
The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis (1996) 1.42
Overview of viral gastroenteritis. Arch Virol Suppl (1996) 1.32
Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl (1999) 1.27
Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000. Pediatr Infect Dis J (2003) 1.15
Epidemiology and impact of rotavirus diarrhoea in Poland. Acta Paediatr Suppl (1999) 1.07
Incidence and estimates of the disease burden of rotavirus in Sweden. Acta Paediatr Suppl (1999) 1.07
Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur J Pediatr (2006) 1.03
International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. Pediatr Infect Dis J (2001) 0.99
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet (1999) 0.98
European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr (2008) 0.96
Prospective population-based study on rotavirus disease in Germany. Acta Paediatr (2002) 0.93
Epidemiology of rotavirus infections in The Netherlands. Acta Paediatr Suppl (1999) 0.91
The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) (2008) 0.90
Occurrence and impact of community-acquired and nosocomial rotavirus infections--a hospital-based study over 10 y. Acta Paediatr Suppl (1999) 0.89
Rotavirus gastroenteritis among children under five years of age in Valencia, Spain. Pediatr Infect Dis J (2006) 0.87
Rotavirus in Ireland: national estimates of disease burden, 1997 to 1998. Pediatr Infect Dis J (2001) 0.87
[Rotavirus gastroenteritis in infants and children. Results of a prospective study in the area of Geneva and Basel 1997/1998 (RoMoS). RoMoS Study Group]. Schweiz Med Wochenschr (1999) 0.83
Epidemiology and burden of rotavirus diarrhea in day care centers in Lyon, France. Eur J Pediatr (2006) 0.81
Gastroenteritis by rotavirus in Spanish children. Analysis of the disease burden. Eur J Pediatr (2007) 0.80
Population-based epidemiology of rotavirus hospitalisations in Switzerland. Swiss Med Wkly (2006) 0.78
Rotavirus infection among children with diarrhoea in Italy. Acta Paediatr Suppl (1999) 0.77
Rotavirus gastroenteritis: epidemiological data from a regional hospital in Belgium. Eur J Pediatr (2007) 0.75
Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2010) 1.99
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.66
Three-year surveillance of intussusception in children in Switzerland. Pediatrics (2007) 1.45
Correlation between bacteriologic eradication and clinical cure in acute otitis media. Pediatr Infect Dis J (2004) 1.39
Influenza vaccination among healthcare workers in a university children's hospital. Infect Control Hosp Epidemiol (2005) 1.32
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J (2012) 1.19
Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr (2005) 1.14
How do physicians immunize their own children? Differences among pediatricians and nonpediatricians. Pediatrics (2005) 1.13
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. Pediatr Infect Dis J (2015) 1.12
Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age. Vaccine (2006) 1.12
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine (2002) 1.11
Addressing the needs and gaps in safety assessment of vaccines during clinical trials in resource limited countries. Vaccine (2011) 1.09
Standardised case definitions for adverse events following immunisation. Lancet (2013) 1.09
Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J (2004) 1.09
The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis (2002) 1.04
Intussusception: incidence and treatment-insights from the nationwide German surveillance. J Pediatr Gastroenterol Nutr (2011) 1.03
Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine (2011) 1.02
Health burden of pertussis in infants and children. Pediatr Infect Dis J (2005) 0.99
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine (2007) 0.94
Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis (2004) 0.94
Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine (2008) 0.94
Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine (2005) 0.93
Neonatal and pediatric antimicrobial stewardship programs in Europe-defining the research agenda. Pediatr Infect Dis J (2013) 0.93
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol (2010) 0.93
Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr (2004) 0.93
Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J (2004) 0.92
Prospective pertussis surveillance in Switzerland, 1991-2006. Vaccine (2011) 0.91
Comparative coverage of supplementary and universally recommended immunizations in children at 24 months of age. Pediatr Infect Dis J (2012) 0.91
The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) (2008) 0.90
No temporal association between influenza outbreaks and invasive pneumococcal infections. Arch Dis Child (2007) 0.90
Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol (2006) 0.90
Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr (2002) 0.90
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine (2007) 0.88
Etiology of aseptic meningitis, peripheral facial nerve palsy, and a combination of both in children. Pediatr Infect Dis J (2010) 0.87
Mycobacterium bohemicum--a cause of paediatric cervical lymphadenitis. Swiss Med Wkly (2004) 0.86
Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine (2008) 0.86
Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in north-western Switzerland. Eur J Pediatr (2005) 0.86
Prevalence of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in children a multicenter cross-sectional study. Pediatr Infect Dis J (2007) 0.86
Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin (2009) 0.85
Clinical findings and unusual epidemiologic characteristics of human metapneumovirus infections in children in the region of Basel, Switzerland. Eur J Pediatr (2007) 0.85
Rotavirus disease in Germany--a prospective survey of very severe cases. Pediatr Infect Dis J (2013) 0.85
Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. Eur J Pediatr (2005) 0.85
A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with Staphylococcus aureus in patients admitted to children's hospitals in Switzerland. Clin Infect Dis (2008) 0.85
Template protocol for clinical trials investigating vaccines--focus on safety elements. Vaccine (2013) 0.84
Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine (2004) 0.84
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin Vaccine Immunol (2006) 0.84
Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine (2013) 0.84
Standardized case definitions of adverse events following immunization (AEFI). Vaccine (2004) 0.83
The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf (2003) 0.83
Adverse events following immunization: perception and evidence. Curr Opin Infect Dis (2007) 0.83
Reliability of varicella history in children and adolescents. Swiss Med Wkly (2005) 0.83
Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) (2004) 0.83
Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine (2003) 0.82
Prospective study on central venous line associated bloodstream infections. Arch Dis Child (2011) 0.82
Prospective surveillance of nosocomial viral infections during and after hospitalization at a university children's hospital. Pediatr Infect Dis J (2010) 0.82
Incidence and Outcome of Group B Streptococcal Sepsis in Infants in Switzerland. Pediatr Infect Dis J (2016) 0.81
Prevalence of nosocomial infections in Swiss children's hospitals. Infect Control Hosp Epidemiol (2004) 0.81
Fever following immunization. Expert Rev Vaccines (2005) 0.81
Human metapneumovirus infections--biannual epidemics and clinical findings in children in the region of Basel, Switzerland. Eur J Pediatr (2009) 0.81
Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr (2004) 0.81
Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J (2004) 0.81
The Brighton Collaboration-enhancing vaccine safety. Vaccine (2004) 0.80
Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland. Hum Vaccin (2009) 0.80
Evaluation of the Brighton Collaboration case definition of acute intussusception during active surveillance. Vaccine (2005) 0.78
Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol (2007) 0.78
A retrospective analysis of nosocomial viral gastrointestinal and respiratory tract infections. Pediatr Infect Dis J (2012) 0.78
Health care-associated rotavirus illness in pediatric inpatients in Germany, Austria, and Switzerland. Infect Control Hosp Epidemiol (2006) 0.77
Protection against vaccine-preventable diseases in medical students. Pediatr Infect Dis J (2003) 0.77
Attitudes of pediatricians regarding influenza self-immunization: a survey in a Swiss university children's hospital. Pediatr Infect Dis J (2003) 0.77
Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS One (2013) 0.77
Interstrain antigenic variability of mumps viruses. Clin Infect Dis (2008) 0.77
Virosome influenza vaccine in children. Vaccine (2002) 0.76
Interpretation of primary care physicians' attitude regarding rotavirus immunisation using diffusion of innovation theories. Vaccine (2009) 0.76
Protection against vaccine-preventable diseases in medical students: a follow up. Pediatr Infect Dis J (2014) 0.76
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000-2013. Pediatr Infect Dis J (2015) 0.76
Comment on findings of Hodge et al. Respirology (2004) 0.75
Comment: clinical implications of endotoxin concentrations in vaccines. Ann Pharmacother (2002) 0.75
Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine (2005) 0.75
Shortage of vaccines: USA, Europe, who next? Arch Dis Child (2002) 0.75
Antibiotic treatment of pertussis: are 7 days really sufficient? Pediatr Infect Dis J (2015) 0.75